MicroPort<sup>®</sup> NeuroTech Attends CINS 2017

Beijing, China - MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") recently attended the 3rd Annual Conference of Chinese Interventional Neuroradiology Society of Chinese Stroke Association ("CINS 2017"). As one of the most influential academic congresses in the field of neurointervention, the CINS 2017 invited renowned domestic and international neurointervention experts to participate in the case contest and share the latest academic achievements.
The opening speech was chaired by Professor Xinjian Yang of Beijing Tiantan Hospital. Professor Zhongrong Miao, Chairman of the CINS 2017, delivered the opening speech in which he showed his determination to learn from the hard-work spirit of neurointerventional experts to contribute to the development of China's neurointervention industry. Professor Zhongxue Wu of Beijing Tiantan Hospital expressed his expectation on behalf of senior neurointional professionals, encouraging the experts in attendance to find better solutions for the treatment of stroke with joint efforts.
 
During the congress, Professor Liangfu Zhu of Henan Provincial People's Hospital delivered a speech of the application of balloon dilation stent in acute artery occlusion, in which he shared his clinical experience in APOLLO Intracranial Stent System ("APOLLO") and had in-depth discussion with experts in attendance. Professor Zhu analyzed the advantages of APOLLO with high recognition in its safety and efficacy. He also shared the tips and tricks in using the device.
 
APOLLO was designed for the treatment of ischemic cerebrovascular disease. It was first approved by China Food and Drug Administration in 2004. It was China's first intracranial stent for the treatment of ischemic cerebrovascular disease caused by symptomatic intracranial atherosclerotic disease. It was awarded the second prize of Shanghai Scientific Progress Award in 2009, named Shanghai Key New Product in 2010, and then listed in the National Key New Product Scheme in 2011. In the future, MicroPort® NeuroTech will continue to devote itself to innovation to provide more safe and effective products and solutions for patients.